MitraClip-related infective endocarditis in a frail, elderly patient: a case report

Kevin Leow 1*, Courtney Isreb 1, and Martin Brown 1,2

1Department of Cardiology, Northern Beaches Hospital, 105 Frenchs Forest Road West, Frenchs Forest, New South Wales 2086, Australia; and 2The Faculty of Medicine, Health and Human Sciences, Level 3, 75 Talavera Rd, Macquarie University, New South Wales 2109, Australia

Received 18 February 2020; first decision 15 April 2020; accepted 22 July 2020; online publish-ahead-of-print 19 September 2020

Background

The incidence of infective endocarditis (IE) following a MitraClip is rare with 17 reported cases in the literature. The reported mortality rate is high, at 41%, despite both medical and surgical therapies. To date, this is the first documented case of IE following a MitraClip procedure in Australia.

Case summary

An 88-year-old male presented with a 1-week history of confusion and dyspnoea. Clinical examination was significant for a temperature of 37.7°C, a pansystolic murmur and bilateral pitting oedema to mid-shin, but no peripheral stigmata of IE. His history included a MitraClip procedure 11 weeks prior for severe mitral regurgitation. Initial blood cultures grew enterococcus faecalis. A transthoracic echocardiogram did not identify vegetations on the MitraClip. Subsequent transoesophageal echocardiogram (TOE) identified a 4 mm × 2 mm echodensity on the posterior mitral valve leaflet suggestive of IE. He was deemed not suitable for surgical intervention due to poor cognitive reserve and his medical comorbidities, so he commenced intravenous (IV) Ampicillin and Ceftriaxone which was later changed to Benzylpenicillin. Repeat TOE 2 weeks later showed the vegetation to have increased to ~1 cm in length, so his treatment was reverted to Ampicillin. A further TOE 4 weeks later showed reduction in size to 5 mm × 2 mm. After 6 weeks of IV antibiotics, the patient was discharged on lifelong oral antibiotics.

Discussion

Infective endocarditis following MitraClip procedure is rare. This disease has a high mortality rate despite optimal medical and surgical therapy. Increased awareness amongst clinicians is important given an increasing volume of MitraClip procedures.

Keywords

MitraClip • Infective endocarditis • Case report

Learning points

• Infective endocarditis following MitraClip device insertion is less common than following prosthetic valve replacement or transcatheter aortic valve implantation.
• The most common causative organism is Staphylococcus aureus.
• With an increasing volume of MitraClip procedures being performed worldwide, clinicians need to be increasingly aware of this potentially fatal complication.
Introduction

Although infective endocarditis (IE) following a prosthetic valve replacement is a well-documented complication, the incidence of IE following a MitraClip is rare with 17 reported cases in the literature. The reported mortality rate is high, at 41%, despite both medical and surgical therapies. To date, this is the first documented case of IE following a MitraClip procedure in Australia. As the incidence of MitraClip procedures increases, awareness of this complication and its management in patients deemed high-risk surgical candidates is essential.

Timeline

3 months prior to admission
MitraClip insertion for severe mitral regurgitation

Day 0
Presented to hospital with increased confusion and fevers. Commenced on Ampicillin, Flucloxacillin, and Gentamicin for fever of unknown origin

Day 2
Gram-positive cocci identified on blood culture

Day 3
Bacteria identified as enterococcus faecalis. Continued on Ampicillin and commenced on Ceftriaxone

Day 6
A 4 mm × 2 mm MitraClip vegetation identified on transoesophageal echocardiography

Day 14
Changed from Ampicillin to Benzylpenicillin to help with ease of administration of antibiotics

Day 22
Repeat transoesophageal echocardiogram (TOE) demonstrating increase in vegetation size up to 10 mm. Changed back from Benzylpenicillin to Ampicillin

Day 42
Repeat TOE demonstrating decrease in vegetation size to 5 mm × 2 mm, with an 8 mm strand on the atrial side

Day 46
Final dose of intravenous antibiotics, to complete a 6-week course

Day 47
Discharged home on lifelong oral Amoxicillin

4 weeks after discharge
Patient did not attend follow-up appointment

Case presentation

An 88-year-old male presented to our hospital with acute confusion. He had a 1-week history of increasing confusion prior to this presentation, as well as increasing dyspnoea. On examination he was pyrexial at 37.7°C, with a pansystolic murmur on auscultation, pitting oedema to his mid-shins bilaterally and signs of chronic venous insufficiency. He had no peripheral stigmata of IE or other signs of infection. His history was significant for a MitraClip operation performed 11 weeks prior to the current presentation for severe mitral regurgitation (MR). Post-MitraClip implantation the patient had received 24 h of intravenous (IV) Cefazolin. Other history included stenting to the left anterior descending artery, chronic kidney disease (creatinine 187.2 mg/L, normal range < 3.0 mg/L), cognitive impairment, and previous back surgery. Admission medications included Pantoprazole, Aspirin, Clopidogrel, Pregabalin, Furosemide, Ramipril, Macuvision, and Chlorvescent. A septic screen was performed including blood and urine cultures and he received IV Gentamicin and Flucloxacillin to cover for sepsis of unknown origin. His C-reactive protein was significantly elevated at 187.2 mg/L (normal range < 5), with an initial normal white cell count. A computed tomography (CT) chest was performed which was consistent with interstitial lung disease. The following day he went into new atrial fibrillation with rapid ventricular response. Blood cultures showed Gram-positive cocci (enterococcus faecalis), sensitive to Ampicillin, Amoxicillin, and Vancomycin. The urine culture was negative, and a magnetic resonance imaging of the brain demonstrated global atrophy and microvascular change, without evidence of septic foci.

His antibiotic regime was changed to IV Ampicillin 2 g 4 hourly. He underwent a CT abdomen pelvis which did not identify a source for enterococcus faecalis bacteraemia. Considering his MitraClip, and with no other source of bacteraemia identified, he underwent a transthoracic echocardiogram (Figure 1) which did not identify any conclusive vegetations. He subsequently underwent a transoesophageal echocardiogram (TOE) which confirmed the presence of a 4 mm × 2 mm echodensity on atrial side of the prolapsing posterior mitral valve leaflet, concerning for a vegetation (Figure 2). Other findings included moderate mitral stenosis, persistent mild-moderate mitral regurgitation (Video 1), and likely rupture chordae. Differentials for this lesion included thrombus, fibrin, redundant leaflet tissue, or malignancy. However, these did not fit the clinical picture of an enterococcus faecalis sepsis of unknown source and recent MitraClip procedure.

Due to his age and the presence of a concurrent delirium on the background of underlying cognitive impairment, he was deemed unsuitable for surgical mitral valve replacement. His treatment plan was...
for 6 weeks of IV antibiotics (Ampicillin 2 g 4 hourly as well as Ceftriaxone for synergistic therapy), followed by lifelong oral amoxicillin. After 2 weeks on IV therapy, he was changed from Ampicillin to Benzylpenicillin to assist with the logistics of administration on discharge. A follow-up TOE (Figure 3) was performed ~3 weeks into treatment which showed an increase in vegetation size to ~1 cm, compared to a previous 4 mm. In discussion with the infectious disease team, this was thought secondary to the development of a mature biofilm. At that point he was switched back from Benzylpenicillin to Ampicillin, with synergistic Ceftriaxone. He also received 1 week of Metronidazole to cover for a presumed aspiration pneumonia 3 weeks after presentation. After completing 6 weeks of IV, a repeat TOE (Figure 4) showed a reduction in size of the vegetation to 5 mm x 2 mm, with a mobile 8 mm strand on the atrial side of the mitral valve. He was discharged on lifelong oral Amoxicillin 1 g 6 hourly and was to be followed up by a cardiologist after 4 weeks. The patient did not attend for follow-up at 4 weeks and their status is unknown at this time.

Discussion

The incidence of IE following prosthetic valve replacement ranges from 1% to 6%, with these rates falling to between 0.5% and 3.1% for transcatheter aortic valve implantation (TAVI). By comparison, IE following MitraClip procedure is a rarer occurrence, with large international registries reporting the incidence to be somewhere between 0% and 2.4%. To date, there has not been any report of IE cases post-MitraClip procedure in Australia.
The average age of the cases from our review was 70.3 years and patients tended to have multiple, complex medical comorbidities (including previous coronary artery bypass surgery, chronic obstructive pulmonary disease, chronic kidney disease/dialysis, or previous stroke).

The most common organism was *Staphylococcus aureus*, accounting for 47.1% of cases. There have been only two prior reported cases with enterococcus faecalis as the causative organism (11.8% of cases). There have also been isolated reports of *Bartonella henselae*, *Staphylococcus epidermidis*, Methicillin-resistant *Staphylococcus aureus*, and α-haemolytic *Streptococcus* as the causative organism. It is interesting to note that although a seemingly rare cause of IE post-MitraClip procedure, enterococcus faecalis is one of the more common causative organisms of IE post-TAVI accounting for up to 21% of cases. In the majority of cases, surgical intervention (70.6%) remained the treatment of choice though post-operative mortality remained high (33%) in this patient population. This is likely reflective of the significant patient comorbidities, with an average preoperative EuroSCORE of 35.94% indicating a high probability of post-procedural in-hospital death. In the cases where medical therapy was utilized, surgical management was often deemed too high risk given underlying patient comorbidities and high preoperative EuroSCORE. This is similar to our case, in which a poor baseline cognition combined with multiple medical comorbidities made our patient a poor surgical candidate. Of the reported cases that were managed medically, mortality was high at 60% with multiorgan failure identified as the main cause of death.

Within a select group of patients with severe mitral regurgitation, MitraClip procedure remains a viable option. Although there is a relatively low incidence rate of IE post-MitraClip compared to other valvular procedures, IE remains a significant post-procedural complication with high mortality and morbidity. Given the increasing volume of MitraClip procedures being performed, it is important that proceduralists remain wary of this potentially fatal complication and its management.

**Lead author biography**

Dr Kevin Leow (MBBS) is a physician trainee with Northern Beaches Hospital. His areas of interest include primary prevention of cardiac diseases and cardiac imaging.

### Supplementary material

**Supplementary material** is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

**Conflict of interest:** none declared.

### References

1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2015;36:3075–3128.

2. Olsen NT, De Backer O, Thyregod HG, Vejlstrup N, Bundgaard H, Sandergaard L et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2015;8:e001739.

3. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerasik S, Cheema AN et al. Infective endocarditis after transcatheter aortic valve implantation results from a Large Multicenter Registry. Circulation 2015;131:1566–1574.

4. Regueiro A, Linke A, Lasb A, Ihlemann N, Urena M, Walther T et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 2016;316:1083–1092.

5. Yeo I, Kim L, Wong C, Cheung J, Itagaki S, Chikwe J et al. Relation of hospital volume with in-hospital and 90-day outcomes after transcatheter mitral valve repair using MitraClip. Am J Cardiol 2019;124:63–69.

6. Stone GW, Lindenfeld JA, Abraham WT, Kar S, Lim DS, Mishell JM et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307–2318.

7. Eggbrecht H, Schelle S, Puls M, Plicht B, von Bardeleben RS, Butter C et al. Risk and outcomes of complications during and after MitraClip implantation: experience in 828 patients from the German TRANscatheter Mitral Valve Interventions (TRAMI) registry. Catheter Cardiovasc Interv 2015;86:728–735.

8. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1405–1416.

9. Kar S, Feldman T, Qasim A, Trento A, Kapadia S, Pedersen W et al. Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients. Heartr 2019;105:1622–1627.

10. Ailawadi G, Scott LM, Mack M, Trento A, Kar S, Grayburn P et al.; On behalf of the EVEREST II Investigators. One-year outcomes after MitraClip for functional mitral regurgitation. Circulation 2019;139:37–47.

11. Weas E, Dwivedi A, Vainrib AF, Yurdutoky E, Benenstein RJJ, Staniloaie C et al. Enterococcus faecalis infective endocarditis following percutaneous edge-to-edge mitral valve repair. Struct Heart 2017;1:293–295.

12. Russo M, Andrews M, Taramasso M, Maisano F, Weber A. Prosthetic valve endocarditis involving the MitraClip device. J Card Surg 2017;32:696–697.

13. Herrmanns H, Wiegnernd E, Lagrand W, Baan J Jr, Cocciere R, Kaya A. Two cases of endocarditis after MitraClip procedure necessitating surgical mitral valve replacement. Ann Thorac Surg 2019;107:e101–e103.

14. Vazir A, Franzen O, Moat N, Price S. Infective endocarditis associated with the MitroClip. In Feldman T, Franzen O, Low R, Rogers J, Yeo K, eds. Atlas of Percutaneous Edge-to-Edge Mitral Valve Repair. London: Springer; 2013.

15. Rosan A, Kamsani S, Akifanus A, Krohnin M, Hakim N, Samsudin W. Butterfly in the heart: infective endocarditis after MitraClip procedure. Case 2018;2:63–65.